This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Healthy Adult Subjects

Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

Sponsored by Ono Pharma USA Inc

About this trial

Last updated 13 years ago

Study ID

ONO-2952POU001

Status

Completed

Type

Interventional

Phase

Phase 1

Placebo

Yes

Accepting

18-75 Years
18 to 55 Years
All
All

Trial Timing

Started 14 years ago

What is this trial about?

The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending single doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952. The tertiary objective of this study is to preliminarily evaluate the effect of a meal upon the PK profile of ONO-2952.

What are the participation requirements?

Yes

Inclusion Criteria

- Healthy non-smoking male or female subjects (18-55 inclusive)

- Body mass index (BMI) of 19-35 kg/m2 (inclusive)

- For females, surgically sterilized, postmenopausal, or who are non- lactating and agree to use a double barrier method of contraception

No

Exclusion Criteria

- History or presence of clinically significant disease

Locations

Location

Status